Fig. 1 · Structure

Documents & Downloads

Photochlor

Cat. No. A13824 CAS 149402-51-7
Photochlor is a lipophilic, second-generation, chlorin-based photosensitizer. Upon intravenous administration, HPPH selectively accumulates in the cytoplasm of cancer or pre-cancerous cells.

In Stock

Publications for Photochlor

2 publications citing this product

  1. Dobson J, .et al. , Vet J, 2018, Mar;233:8-18 PMID: 29486883
  2. Moghissi K, .et al. , Surg J (N Y)., 2015, Oct 15;1(1):e1-e15 PMID: 28824964

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Photochlor (HPPH) has been studied as a photosensitizer for photodynamic therapy. In lung-cell cultures, HPPH followed by illumination produced STAT3 crosslinking associated with cell killing. Crosslinking served as a photoreaction marker; these experiments do not establish HPPH as a selective STAT3 inhibitor. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 0.33 μM Phototoxicity against human A549 cells assessed as reduction in cell proliferation irradiated with 1 J/cm2 of 650 nanometer laser light preincubated for 24 hrs measured after 48 hrs by MTT assay [PMID: 31846830]
FaDu IC50 43.8 nM Photosensitizing activity in human FaDu cells assessed as reduction in cell viability pretreated with compound for 24 hrs followed by light irradiation at 1 J/cm2 and measured after 48 hrs by MTT assay [PMID: 33400524]
UMUC3 IC50 68.4 nM Photosensitizing activity in human UMUC3 cells assessed as reduction in cell viability pretreated with compound for 24 hrs followed by light irradiation at 1 J/cm2 and measured after 48 hrs by MTT assay [PMID: 33400524]

Photochlor Research Summary

This section summarizes 2 in vitro studies and 3 in vivo studies of Photochlor from 3 published references. In vitro models include TEC-1–2 co-cultured with labeled human T-Fb.

Photochlor In Vitro Studies

HPPH-PDT responses varied with cell type and photosensitizer retention. Lung epithelial cultures, including non-tumor epithelial cells, were more sensitive than tumor-associated fibroblasts at comparable STAT3 crosslinking. In co-cultures, low-retaining tumor clusters survived and resumed proliferation, limiting claims of uniform tumor-cell elimination. [1]

HPPH photoreaction and survival in lung epithelial cells and fibroblasts

Cell-based study · Primary human normal and tumor lung epithelial cultures; TEC-1–2 lung tumor cells; tumor-associated fibroblasts (T-Fb). Figure 2: L374 N-EC/T-EC, passage 3. [1]

After HPPH loading and washout, illumination generated STAT3 crosslinked complexes and reduced epithelial survival. Compiled cultures linked the extent of photoreaction to killing, with fibroblasts less sensitive. Normal epithelial cells were also susceptible; this does not establish universal tumor selectivity or direct inhibition of STAT3.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
STAT3 crosslinking associated with essentially complete epithelial killingReported approximate association ~2% STAT3 crosslinking associated with essentially 100% lethality in HPPH-treated epithelial cultures[1]
Fibroblast photoreaction associated with complete killingReported approximate association ~10–20% STAT3 crosslinking to achieve 100% lethality in T-Fb[1]

Literature-Reported Treatment Conditions

Treatment concentration
Figure 2 HPPH: 0, 25, 50 and 100 nM (image labels). Compiled cultures in Figures 3–4 used multiple concentrations; no complete concentration series is specified in their captions.
Exposure duration
24 h photosensitizer incubation, then 24 h chase in photosensitizer-free medium; immediate immunoblot analysis or survival assessment 24 h after illumination.
Method
RPMI with 10% FBS for Figure 2. General photoreaction method: 665 or 675 nm light, 5.6 mW/cm² for 9 min, total fluence 3 J/cm².
Vehicle
Stock: 5% glucose in water containing 2% ethanol and 0.1% Tween 80; diluted into the specified culture medium. Final excipient fractions are not specified.
Co-treatment
PDT requires HPPH plus illumination; HPPH-Lac was a separately tested structural comparator, not interchangeable HPPH.
Reported limits
Exact wavelength assignment to individual panels is not specified. Figure 2 has a zero-photosensitizer control; selected figure captions do not specify a separately quantified time-matched HPPH-only dark-survival arm. No IC50 is adopted.
Methods and source locations

Compound reported in the paper: Photochlor (HPPH); Compound label in the paper: HPPH

Evidence concerns the reported HPPH preparation under the stated model and illumination conditions. Exact stereoisomer composition and equivalence to an Adooq lot were not established.

Figures 2–4 and captions; Results: Photoreaction mediated by mitochondrial and lysosomal HPPH; Quantitative relationship of HPPH concentration and PDT response; Materials and Methods

STAT3 crosslinking associated with essentially complete epithelial killing: STAT3 immunoblot: percent monomer converted to homodimeric form I; viable-cell count by trypan-blue exclusion 24 h after light. — Figure 4A–C; Results: Quantitative relationship of HPPH concentration and PDT response

Fibroblast photoreaction associated with complete killing: Parallel survival and STAT3 immunoblot measurements; cell-type comparison, not a drug potency concentration. — Figure 4D; same Results subsection

Heterogeneous HPPH retention and post-PDT fate in lung tumor–fibroblast co-cultures

Cell-based study · TEC-1–2 (passage 37) co-cultured with labeled human T-Fb (L323). [1]

Higher-retaining tumor clusters were damaged after PDT while fibroblasts survived and entered cleared sites. Low-retaining tumor clusters survived and resumed proliferation. The images support heterogeneous response, not eradication of every tumor cell.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fate of low-HPPH tumor clusters after PDTQualitative microscopy Surviving low-retaining TEC-1–2 clusters resumed proliferation; no numerical surviving fraction reported[1]

Literature-Reported Treatment Conditions

Treatment concentration
800 nM HPPH
Exposure duration
24 h loading, 24 h chase in HPPH-free medium; images before PDT and daily for 3 days afterward.
Method
DMEM with 10% FBS. General illumination method: 665 or 675 nm, 3 J/cm² over 9 min at 5.6 mW/cm².
Vehicle
Stock: 5% glucose in water containing 2% ethanol and 0.1% Tween 80; diluted into the specified culture medium. Final excipient fractions are not specified.
Co-treatment
HPPH plus therapeutic light; labeled fibroblasts provide cell-type discrimination.
Reported limits
Exact wavelength for Figure 5 and quantitative replicate count are not specified in the caption. This is an illustrative longitudinal imaging design, not a numerical tumor-kill assay; a matched dark-treated image series is not provided in Figure 5.
Methods and source locations

Compound reported in the paper: Photochlor (HPPH); Compound label in the paper: HPPH

Evidence concerns the reported HPPH preparation under the stated model and illumination conditions. Exact stereoisomer composition and equivalence to an Adooq lot were not established.

Figure 5 and caption; Results: Quantitative relationship of HPPH concentration and PDT response (co-culture paragraphs); Methods: PS uptake and photoreaction

Fate of low-HPPH tumor clusters after PDT: Phase contrast, HPPH fluorescence and fibroblast-label imaging over 3 days. — Figure 5, rightmost panel and caption; co-culture Results paragraphs

Photochlor In Vivo Studies

In mice with disseminated intrathoracic H460 tumors, HPPH-PDT reduced short-term tumor burden under selected illumination conditions, but responses depended on the model and light regimen. A later reporter-labeled H460 model showed significant reduction at 75 mW/cm and only nonsignificant trends at 150 mW/cm; parental H460 cells responded at both rates. Increasing light fluence in the earlier study increased mortality, and normal-lung injury occurred after PDT. These results support condition-specific preclinical activity with a constrained therapeutic window. [2,3]

Intrathoracic HPPH-PDT: tumor mass and treatment-related mortality

Animal study · Female athymic Ncr-nu/nu mice, 7–9 weeks old, bearing disseminated intrathoracic parental H460 human lung carcinoma. [2]

Tumor mass at four days was lower after PDT at 50–200 J/cm but not at 25 J/cm. Drug-only and light-only controls did not differ significantly from untreated animals. Mortality increased with fluence; tumor-mass results at high fluence reflect the animals available for necropsy and are not evidence of safe tumor eradication.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mortality through 4 days after PDTReported mortality proportion 25, 50, 80, 150 and 200 J/cm: 8%, 11%, 38%, 54% and 50%, respectively[2]
Odds of death per 25 J/cm increase in fluenceLogistic regression odds ratio 1.9-fold (95% CI: 1.5, 2.4; p<0.0001)[2]

Conditions shared by the study groups

Treatment course
~24 h before illumination for PDT arms; tumor mass collected 4 days after PDT or corresponding control treatment.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
UntreatedUntreated group; also HPPH-only and 80 J/cm light-only controls.Aggregate tumor mass, mean ± SD: 0.2636 ± 0.0810 g; n=17; reference group. p values compare with untreated.[2]
Light only (80 J/cm)Untreated group; also HPPH-only and 80 J/cm light-only controls.Aggregate tumor mass, mean ± SD: 0.2345 ± 0.1212 g; n=5; p=0.6661. p values compare with untreated.[2]
HPPH only
1 mg/kg
Untreated group; also HPPH-only and 80 J/cm light-only controls.Aggregate tumor mass, mean ± SD: 0.2928 ± 0.0805 g; n=11; p=0.4373. p values compare with untreated.[2]
PDT 25 J/cm
1 mg/kg
Untreated group; also HPPH-only and 80 J/cm light-only controls.Aggregate tumor mass, mean ± SD: 0.2464 ± 0.1016 g; n=11; p=0.6891. p values compare with untreated.[2]
PDT 50 J/cm
1 mg/kg
Untreated group; also HPPH-only and 80 J/cm light-only controls.Aggregate tumor mass, mean ± SD: 0.1112 ± 0.0570 g; n=15; p<0.0001. p values compare with untreated.[2]
PDT 80 J/cm
1 mg/kg
Untreated group; also HPPH-only and 80 J/cm light-only controls.Aggregate tumor mass, mean ± SD: 0.1158 ± 0.0738 g; n=14; p<0.0001. p values compare with untreated.[2]
PDT 150 J/cm
1 mg/kg
Untreated group; also HPPH-only and 80 J/cm light-only controls.Aggregate tumor mass, mean ± SD: 0.0829 ± 0.0447 g; n=6; p=0.0010. p values compare with untreated.[2]
PDT 200 J/cm
1 mg/kg
Untreated group; also HPPH-only and 80 J/cm light-only controls.Aggregate tumor mass, mean ± SD: 0.1132 ± 0.0069 g; n=2; p=0.0236. p values compare with untreated.[2]
Untreated
Model: Female athymic Ncr-nu/nu mice, 7–9 weeks old, bearing disseminated intrathoracic parental H460 human lung carcinoma.
Reported limits: n is the Table 1 necropsy sample size, not the number initially assigned. High-fluence groups were curtailed because of mortality.
Light only (80 J/cm)
Model: Female athymic Ncr-nu/nu mice, 7–9 weeks old, bearing disseminated intrathoracic parental H460 human lung carcinoma.
Reported limits: n is the Table 1 necropsy sample size, not the number initially assigned. High-fluence groups were curtailed because of mortality.
HPPH only
Model: Female athymic Ncr-nu/nu mice, 7–9 weeks old, bearing disseminated intrathoracic parental H460 human lung carcinoma.
Route: Intravenous tail vein
Frequency: Single HPPH administration
Vehicle: Stock in 5% dextrose in water with 2% ethyl alcohol (95%) and 1% polysorbate 80; diluted in D5W to 0.1 mg/mL HPPH. Stock adjusted to pH 7.3–7.5.
Reported limits: n is the Table 1 necropsy sample size, not the number initially assigned. High-fluence groups were curtailed because of mortality.
PDT 25 J/cm
Model: Female athymic Ncr-nu/nu mice, 7–9 weeks old, bearing disseminated intrathoracic parental H460 human lung carcinoma.
Route: Intravenous tail vein
Frequency: Single HPPH administration
Vehicle: Stock in 5% dextrose in water with 2% ethyl alcohol (95%) and 1% polysorbate 80; diluted in D5W to 0.1 mg/mL HPPH. Stock adjusted to pH 7.3–7.5.
Reported limits: n is the Table 1 necropsy sample size, not the number initially assigned. High-fluence groups were curtailed because of mortality.
PDT 50 J/cm
Model: Female athymic Ncr-nu/nu mice, 7–9 weeks old, bearing disseminated intrathoracic parental H460 human lung carcinoma.
Route: Intravenous tail vein
Frequency: Single HPPH administration
Vehicle: Stock in 5% dextrose in water with 2% ethyl alcohol (95%) and 1% polysorbate 80; diluted in D5W to 0.1 mg/mL HPPH. Stock adjusted to pH 7.3–7.5.
Reported limits: n is the Table 1 necropsy sample size, not the number initially assigned. High-fluence groups were curtailed because of mortality.
PDT 80 J/cm
Model: Female athymic Ncr-nu/nu mice, 7–9 weeks old, bearing disseminated intrathoracic parental H460 human lung carcinoma.
Route: Intravenous tail vein
Frequency: Single HPPH administration
Vehicle: Stock in 5% dextrose in water with 2% ethyl alcohol (95%) and 1% polysorbate 80; diluted in D5W to 0.1 mg/mL HPPH. Stock adjusted to pH 7.3–7.5.
Reported limits: n is the Table 1 necropsy sample size, not the number initially assigned. High-fluence groups were curtailed because of mortality.
PDT 150 J/cm
Model: Female athymic Ncr-nu/nu mice, 7–9 weeks old, bearing disseminated intrathoracic parental H460 human lung carcinoma.
Route: Intravenous tail vein
Frequency: Single HPPH administration
Vehicle: Stock in 5% dextrose in water with 2% ethyl alcohol (95%) and 1% polysorbate 80; diluted in D5W to 0.1 mg/mL HPPH. Stock adjusted to pH 7.3–7.5.
Reported limits: n is the Table 1 necropsy sample size, not the number initially assigned. High-fluence groups were curtailed because of mortality.
PDT 200 J/cm
Model: Female athymic Ncr-nu/nu mice, 7–9 weeks old, bearing disseminated intrathoracic parental H460 human lung carcinoma.
Route: Intravenous tail vein
Frequency: Single HPPH administration
Vehicle: Stock in 5% dextrose in water with 2% ethyl alcohol (95%) and 1% polysorbate 80; diluted in D5W to 0.1 mg/mL HPPH. Stock adjusted to pH 7.3–7.5.
Reported limits: n is the Table 1 necropsy sample size, not the number initially assigned. High-fluence groups were curtailed because of mortality.
Methods and source locations

Compound reported in the paper: Photochlor (HPPH); Compound label in the paper: HPPH

Evidence concerns the reported HPPH preparation under the stated model and illumination conditions. Exact stereoisomer composition and equivalence to an Adooq lot were not established.

Table 1 and footnote; Results: feasibility/mortality and tumor-burden paragraphs; Methods: PDT, Assessment of tumor response to PDT, Statistical analysis

Mortality through 4 days after PDT: Observation after PDT. Distinct from acute technical losses: ~11% during fiber placement and ~4.5% during/immediately after PDT attributed to positioning. — Results: first paragraph of intrathoracic PDT feasibility/morbidity discussion; Discussion: fluence-dependent mortality

Odds of death per 25 J/cm increase in fluence: Mortality versus increasing fluence; not a hazard ratio. — Same Results paragraph

Untreated · Table 1 and footnote; Methods: PDT and tumor-response assessment

Light only (80 J/cm) · Table 1 and footnote; Methods: PDT and tumor-response assessment

HPPH only · Table 1 and footnote; Methods: PDT and tumor-response assessment

PDT 25 J/cm · Table 1 and footnote; Methods: PDT and tumor-response assessment

PDT 50 J/cm · Table 1 and footnote; Methods: PDT and tumor-response assessment

PDT 80 J/cm · Table 1 and footnote; Methods: PDT and tumor-response assessment

PDT 150 J/cm · Table 1 and footnote; Methods: PDT and tumor-response assessment

PDT 200 J/cm · Table 1 and footnote; Methods: PDT and tumor-response assessment

Normal-lung injury after intrathoracic HPPH-PDT

Animal study · Tumor-free mice examined for normal thoracic-tissue injury; study uses female athymic Ncr-nu/nu mice. [2]

HPPH-PDT damaged normal lung as well as tumor. Histology showed alveolar/interstitial edema, fibrin and inflammatory cells with focal vascular injury. Light alone also caused tissue changes, generally milder in the lung, so not all injury can be assigned solely to photosensitizer activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Normal-lung histopathologyQualitative blinded histopathology Edema, fibrin deposition, interstitial congestion, neutrophils and focal vascular disruption after PDT; HPPH-only/untreated lungs generally normal; light-only lung changes milder without identified necrotic debris[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Normal lung: untreatedTumor-free untreated, HPPH-only and light-only comparators in the normal-tissue experiment; not the tumor-bearing Table 1 controls.Generally normal lung histology, apart from occasional mild interstitial congestion.[2]
Normal lung: HPPH only
1 mg/kg
Tumor-free untreated, HPPH-only and light-only comparators in the normal-tissue experiment; not the tumor-bearing Table 1 controls.Generally normal lung histology, apart from occasional mild interstitial congestion.[2]
Normal lung: light onlyTumor-free untreated, HPPH-only and light-only comparators in the normal-tissue experiment; not the tumor-bearing Table 1 controls.Vessel-wall changes similar to PDT; interstitial and alveolar changes milder, with no necrotic debris identified.[2]
Normal lung: HPPH-PDT 50 J/cm
1 mg/kg
Tumor-free untreated, HPPH-only and light-only comparators in the normal-tissue experiment; not the tumor-bearing Table 1 controls.Lung interstitial vascular congestion, fibrin and neutrophils; alveolar edema, fibrin, neutrophils and scattered necrotic debris; focal vascular injury. Qualitative pathology, without an inferred lesion score.[2]
Normal lung: untreated
Model: Tumor-free mice examined for normal thoracic-tissue injury; study uses female athymic Ncr-nu/nu mice.
Treatment course: No HPPH or illumination. Histology collection interval not specified.
Reported limits: Histology group sizes and collection interval are not specified for Figure 5; the Table 3 blood collection time and n are not histology data.
Normal lung: HPPH only
Model: Tumor-free mice examined for normal thoracic-tissue injury; study uses female athymic Ncr-nu/nu mice.
Route: Intravenous tail vein
Frequency: Single HPPH administration
Treatment course: HPPH without illumination; histology collection interval not specified.
Vehicle: Stock in 5% dextrose in water with 2% ethyl alcohol (95%) and 1% polysorbate 80; diluted in D5W to 0.1 mg/mL HPPH. Stock adjusted to pH 7.3–7.5.
Reported limits: Histology group sizes and collection interval are not specified for Figure 5; the Table 3 blood collection time and n are not histology data.
Normal lung: light only
Model: Tumor-free mice examined for normal thoracic-tissue injury; study uses female athymic Ncr-nu/nu mice.
Treatment course: Light-only comparator in the normal-tissue experiment, without HPPH. Histology collection interval not specified.
Reported limits: Histology group sizes and collection interval are not specified for Figure 5; the Table 3 blood collection time and n are not histology data. Figure 5 depicts untreated and PDT lungs; light-only findings are from Results text. No separate light-only fluence is assigned from the caption.
Normal lung: HPPH-PDT 50 J/cm
Model: Tumor-free mice examined for normal thoracic-tissue injury; study uses female athymic Ncr-nu/nu mice.
Route: Intravenous tail vein
Frequency: Single HPPH administration
Treatment course: ~24 h drug-light interval; 661 nm intrathoracic illumination at 150 mW/cm to 50 J/cm. Histology collection interval not specified.
Vehicle: Stock in 5% dextrose in water with 2% ethyl alcohol (95%) and 1% polysorbate 80; diluted in D5W to 0.1 mg/mL HPPH. Stock adjusted to pH 7.3–7.5.
Reported limits: Histology group sizes and collection interval are not specified for Figure 5; the Table 3 blood collection time and n are not histology data.
Methods and source locations

Compound reported in the paper: Photochlor (HPPH); Compound label in the paper: HPPH

Evidence concerns the reported HPPH preparation under the stated model and illumination conditions. Exact stereoisomer composition and equivalence to an Adooq lot were not established.

Results: Local normal tissue damage and systemic effects; Figure 5 and caption; Methods: PDT and Pathological evaluation

Normal-lung histopathology: H&E sections; representative 10× images and 20× inset. No lesion score or quantitative incidence is inferred. — Figure 5a–b/caption; Results: Local normal tissue damage and systemic effects

Normal lung: untreated · Retained PMC author manuscript NIHMS456464: #S8 Photodynamic therapy; #S13 Pathological evaluation; #S20 Local normal tissue damage and systemic effects; #F5 caption.

Normal lung: HPPH only · Retained PMC author manuscript NIHMS456464: #S8 Photodynamic therapy; #S13 Pathological evaluation; #S20 Local normal tissue damage and systemic effects; #F5 caption.

Normal lung: light only · Retained PMC author manuscript NIHMS456464: #S8 Photodynamic therapy; #S13 Pathological evaluation; #S20 Local normal tissue damage and systemic effects; #F5 caption.

Normal lung: HPPH-PDT 50 J/cm · Retained PMC author manuscript NIHMS456464: #S8 Photodynamic therapy; #S13 Pathological evaluation; #S20 Local normal tissue damage and systemic effects; #F5 caption.

Fluence-rate and model dependence of HPPH-PDT tumor response

Animal study · Female athymic Ncr-nu/nu mice, 7–9 weeks, with disseminated H460 tumors expressing a luciferase/RFP reporter; parental H460 used for validation. [3]

At 50 J/cm, the labeled H460 model showed significant mass reduction at 75 mW/cm with 1 mg/kg HPPH; both 150 mW/cm conditions showed only nonsignificant trends. Parental H460 responded significantly at both rates. The authors did not establish the cause of the model difference; these are not interchangeable estimates of a universal response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Aggregate mass 4 days after PDT in reporter-labeled H460 tumorsTumor mass; n=8–27 per group (caption range) Mean ± SD (PDT vs pooled control): 75 mW/cm, 1 mg/kg: 0.1246 ± 0.0538 vs 0.2009 ± 0.0998 g (p=0.02); 150 mW/cm, 1 mg/kg: 0.1812 ± 0.0993 vs 0.2293 ± 0.0767 g; 150 mW/cm, 0.5 mg/kg: 0.1931 ± 0.0826 vs 0.2414 ± 0.0861 g. The latter two reductions were nonsignificant trends.[3]
Parental H460 validation under 1 mg/kg HPPH and 50 J/cmTumor mass; mean ± SD for PDT groups Mean ± SD tumor mass: 0.0861 ± 0.0487 g at 75 mW/cm; 0.1191 ± 0.0603 g at 150 mW/cm; both significantly below controls. Control group masses ranged 0.1785–0.1811 g.[3]

Conditions shared by the study groups

Route
Intravenous tail vein
Frequency
Single HPPH administration
Vehicle
Stock in 5% dextrose in water with 2% ethyl alcohol (95%) and 1% polysorbate 80; diluted in D5W to 0.1 mg/mL HPPH. Stock adjusted to pH 7.3–7.5.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Reporter H460: 75 mW/cm, 1 mg/kg
1 mg/kg
Corresponding pooled untreated, dose-matched drug-only and rate-matched light-only controls: mean ± SD 0.2009 ± 0.0998 g. Controls were pooled because they behaved similarly.Aggregate tumor mass, mean ± SD: 0.1246 ± 0.0538 g; p=0.02 vs corresponding pooled control.[3]
Reporter H460: 150 mW/cm, 1 mg/kg
1 mg/kg
Corresponding pooled untreated, dose-matched drug-only and rate-matched light-only controls: mean ± SD 0.2293 ± 0.0767 g. Controls were pooled because they behaved similarly.Aggregate tumor mass, mean ± SD: 0.1812 ± 0.0993 g; nonsignificant downward trend vs corresponding pooled control.[3]
Reporter H460: 150 mW/cm, 0.5 mg/kg
0.5 mg/kg
Corresponding pooled untreated, dose-matched drug-only and rate-matched light-only controls: mean ± SD 0.2414 ± 0.0861 g. Controls were pooled because they behaved similarly.Aggregate tumor mass, mean ± SD: 0.1931 ± 0.0826 g; nonsignificant downward trend vs corresponding pooled control.[3]
Parental H460: 75 mW/cm, 1 mg/kg
1 mg/kg
Parental H460 untreated, light-only and drug-only controls; reported masses range 0.1785–0.1811 g across control conditions. This range is neither an SD nor an assigned rate-specific pooled mean.Aggregate tumor mass, mean ± SD: 0.0861 ± 0.0487 g; significantly reduced vs controls according to Results 2.1.[3]
Parental H460: 150 mW/cm, 1 mg/kg
1 mg/kg
Parental H460 untreated, light-only and drug-only controls; reported masses range 0.1785–0.1811 g across control conditions. This range is neither an SD nor an assigned rate-specific pooled mean.Aggregate tumor mass, mean ± SD: 0.1191 ± 0.0603 g; significantly reduced vs controls according to Results 2.1.[3]
Reporter H460: 75 mW/cm, 1 mg/kg
Model: Female athymic Ncr-nu/nu mice, 7–9 weeks, with disseminated intrathoracic luciferase/RFP reporter-labeled H460 tumors.
Treatment course: PDT on model day 12, ~24 h after HPPH; 661 nm at 75 mW/cm to 50 J/cm. Aggregate tumor mass assessed 4 days later.
Reported limits: Figure 2 caption gives n=8–27 animals per group as a range, without exact arm-specific n. No between-rate p value is reported here.
Reporter H460: 150 mW/cm, 1 mg/kg
Model: Female athymic Ncr-nu/nu mice, 7–9 weeks, with disseminated intrathoracic luciferase/RFP reporter-labeled H460 tumors.
Treatment course: PDT on model day 12, ~24 h after HPPH; 661 nm at 150 mW/cm to 50 J/cm. Aggregate tumor mass assessed 4 days later.
Reported limits: Figure 2 caption gives n=8–27 animals per group as a range, without exact arm-specific n. No between-rate p value is reported here.
Reporter H460: 150 mW/cm, 0.5 mg/kg
Model: Female athymic Ncr-nu/nu mice, 7–9 weeks, with disseminated intrathoracic luciferase/RFP reporter-labeled H460 tumors.
Treatment course: PDT on model day 12, ~24 h after HPPH; 661 nm at 150 mW/cm to 50 J/cm. Aggregate tumor mass assessed 4 days later.
Reported limits: Figure 2 caption gives n=8–27 animals per group as a range, without exact arm-specific n. No between-rate p value is reported here.
Parental H460: 75 mW/cm, 1 mg/kg
Model: Female athymic Ncr-nu/nu mice with disseminated intrathoracic parental H460 tumors; validation distinct from reporter-labeled H460.
Treatment course: Parental-line validation of the same treatment design: ~24 h drug-light interval; 661 nm at 75 mW/cm to 50 J/cm. Tumor mass assessed on day 16, four days after PDT.
Reported limits: Exact parental arm n, exact p value and arm-specific control mean/SD are not provided in this paragraph. Figure 2 reporter-model sample-size range is not assigned to parental groups. Cause of model-response difference remains unknown.
Parental H460: 150 mW/cm, 1 mg/kg
Model: Female athymic Ncr-nu/nu mice with disseminated intrathoracic parental H460 tumors; validation distinct from reporter-labeled H460.
Treatment course: Parental-line validation of the same treatment design: ~24 h drug-light interval; 661 nm at 150 mW/cm to 50 J/cm. Tumor mass assessed on day 16, four days after PDT.
Reported limits: Exact parental arm n, exact p value and arm-specific control mean/SD are not provided in this paragraph. Figure 2 reporter-model sample-size range is not assigned to parental groups. Cause of model-response difference remains unknown.
Methods and source locations

Compound reported in the paper: Photochlor (HPPH); Compound label in the paper: HPPH

Evidence concerns the reported HPPH preparation under the stated model and illumination conditions. Exact stereoisomer composition and equivalence to an Adooq lot were not established.

Results 2.1, Figure 2 and caption; Experimental 3.1–3.2, 3.5

Aggregate mass 4 days after PDT in reporter-labeled H460 tumors: Excision and weighing; Wilcoxon rank-sum comparisons against matched pooled controls. — Results 2.1, first tumor-mass paragraph; Figure 2/caption

Parental H460 validation under 1 mg/kg HPPH and 50 J/cm: Parental-line validation within the fluence-rate experiment. Exact parental group n and p values are not given in this paragraph; the control range is not an SD. — Results 2.1, paragraph following Figure 2 caption

Reporter H460: 75 mW/cm, 1 mg/kg · Retained PMC published article: #sec2dot1-ijms-17-00101 Results 2.1, Figure 2/caption and parental validation; #sec3dot1-ijms-17-00101; #sec3dot2-ijms-17-00101; #sec3dot5-ijms-17-00101.

Reporter H460: 150 mW/cm, 1 mg/kg · Retained PMC published article: #sec2dot1-ijms-17-00101 Results 2.1, Figure 2/caption and parental validation; #sec3dot1-ijms-17-00101; #sec3dot2-ijms-17-00101; #sec3dot5-ijms-17-00101.

Reporter H460: 150 mW/cm, 0.5 mg/kg · Retained PMC published article: #sec2dot1-ijms-17-00101 Results 2.1, Figure 2/caption and parental validation; #sec3dot1-ijms-17-00101; #sec3dot2-ijms-17-00101; #sec3dot5-ijms-17-00101.

Parental H460: 75 mW/cm, 1 mg/kg · Retained PMC published article: #sec2dot1-ijms-17-00101 Results 2.1, Figure 2/caption and parental validation; #sec3dot1-ijms-17-00101; #sec3dot2-ijms-17-00101; #sec3dot5-ijms-17-00101.

Parental H460: 150 mW/cm, 1 mg/kg · Retained PMC published article: #sec2dot1-ijms-17-00101 Results 2.1, Figure 2/caption and parental validation; #sec3dot1-ijms-17-00101; #sec3dot2-ijms-17-00101; #sec3dot5-ijms-17-00101.

Specifications

Manufacturer Adooq Bioscience
CAS Number 149402-51-7
Formula C39H48N4O4
Molecular Weight 636.82
Synonyms HPPH
SMILES
O=C(CC[C@H](C(C1=C(C(C(C1)=O)=C/2C)NC2=C/C3=N/C(C(C)=C3CC)=C\C(N4)=C5C(OCCCCCC)C)=N/C6=C\C4=C5C)[C@@H]6C)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Photochlor Research References

  1. [1] Tracy EC, Bowman MJ, Pandey RK, et al. Cell-specific Retention and Action of Pheophorbide-based Photosensitizers in Human Lung Cancer Cells. Photochemistry and photobiology (2019). PMID: 30378688 DOI: 10.1111/php.13043 Source material
  2. [2] Grossman CE, Pickup S, Durham A, et al. Photodynamic therapy of disseminated non-small cell lung carcinoma in a murine model. Lasers in surgery and medicine (2011). PMID: 22057494 DOI: 10.1002/lsm.21102 Source material
  3. [3] Grossman CE, Carter SL, Czupryna J, et al. Fluence Rate Differences in Photodynamic Therapy Efficacy and Activation of Epidermal Growth Factor Receptor after Treatment of the Tumor-Involved Murine Thoracic Cavity. International journal of molecular sciences (2016). PMID: 26784170 DOI: 10.3390/ijms17010101 Source material

Publications

2 publications citing this product

  1. Dobson J, .et al. , Vet J, 2018, Mar;233:8-18 PMID: 29486883
  2. Moghissi K, .et al. , Surg J (N Y)., 2015, Oct 15;1(1):e1-e15 PMID: 28824964

Added to your cart

View Cart Checkout
Loading...